Volume 1, Issue 20


Cover Image

Cover Figure:  Freely flowing platelets nucleating on arrested neutrophils.
See the article by Jimenez et al.

WASHINGTON, September 12,  2017 – Welcome to the “Advance Notice,”  newsletter which provides highlights from issues of Blood Advances, the open-access journal of the American Society of Hematology (ASH), that  are hand-picked by Blood Advances Editor-in-Chief Robert Negrin, MD.


Vaso-occlusive crises in patients with sickle cell disease are a major ongoing clinical problem. Jimenez et al explore the role of glycoprotein Ibα inhibitor (CCP-224) in neutrophil-platelet aggregation, setting the stage for potential clinical translation.


Vaso-occlusive crises are a major cause of morbidity for patients with sickle cell disease. It is thought that adenosine A2A receptors play a major role in tissue inflammation induced by hypoxia. Field et al hypothesized that the administration of an adenosine A2A receptor agonist might reduce inflammation and activate invariant natural killer T cells. In a randomized phase 2 clinical trial, the A2A receptor agonist regadenoson was compared with a placebo.


The transcription factor RUNX1 plays an important role in hematopoiesis and immune function. In the article by Suzuki et al, the epigenetic role of RUNX1 is explored. Evidence is provided that RUNX1 is important in site-specific DNA methylation in hematopoietic stem cells, furthering the role of this important regulator.


With the understanding of the molecular basis of Philadelphia chromosome–like acute lymphoblastic leukemia comes the opportunity to develop more precise and hopefully effective treatment strategies. Roberts et al explore the oncogenic role and targeting of Abl and JAK-STAT pathways in this disorder, setting the stage for the design of more effective clinical trials.


Featured Visual Abstract

Mature murine megakaryocytes present antigen-MHC class I molecules to T cells and transfer them to platelets

Anne Zufferey, Edwin R. Speck, Kellie R. Machlus, Rukhsana Aslam, Li Guo, Mark J. McVey, Michael Kim, Rick Kapur, Eric Boilard, Joseph E. Italiano Jr and John W. Semple.




Blood Advances is the open-access journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.